Immunic Inc (NASDAQ:IMUX, FRA:10VA) said it will participate in multiple May conferences, including Bio€quity Europe, where CEO Daniel Vitt and IR VP Jessica Breu will meet investors in Prague and virtually.
At the CMSC Annual Meeting in Charlotte, the company will present three posters, including a late-breaking analysis on disability changes in multiple sclerosis, and data from its Phase 2 CALLIPER trial evaluating vidofludimus calcium.